[Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?]. - Université de Bretagne Occidentale Access content directly
Journal Articles Néphrologie & Thérapeutique Year : 2014

[Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].

Emilie Cornec-Le Gall

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent Mendelian inherited disorder. It covers 6.1% of incident ESRD patients in France in 2011. Long left untreated, this disease will soon benefit from targeted therapies currently under evaluation. Several molecules have already reached the stage of clinical trials: the evaluation of mTOR inhibitors yielded deceiving results and, more recently, 2 different molecules demonstrated a slight impact on the progression of total kidney volume (TKV): tolvaptan, vasopressin receptor-V2 inhibitor and somatostatin analogues; both of these molecules acting throughout the decrease of intracellular AMPc. The purpose of this review is to briefly describe the signaling pathways involved, then to present both the published and ongoing clinical trials and the promising molecules evaluated in murine models.

Domains

Immunology
No file

Dates and versions

hal-01128884 , version 1 (10-03-2015)

Identifiers

  • HAL Id : hal-01128884 , version 1
  • PUBMED : 25086476

Cite

Emilie Cornec-Le Gall, Yannick Le Meur. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].. Néphrologie & Thérapeutique, 2014, 10 (6), pp.433-40. ⟨hal-01128884⟩

Collections

UNIV-BREST IMMUNO
33 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More